Department of Medical Imaging, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
J Med Imaging Radiat Oncol. 2021 Jun;65(3):333-334. doi: 10.1111/1754-9485.13136. Epub 2020 Dec 26.
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PSMA)-based PET imaging, have substantially improved the sensitivity and specificity of PET imaging. 18F-Fluoroestradiol (FES) is a novel PET tracer that has been demonstrated to have high specificity for oestrogen receptor (ER) in breast cancer. This case describes the use of FES-PET to further characterise a solitary scapular lesion in a patient with locally advanced ER-positive breast cancer. In demonstrating FES avidity in the lesion, it was determined to represent metastatic disease, thus avoiding further biopsy with its associated morbidity. This case demonstrates the potential diagnostic utility of FES PET-CT in the management of ER-positive breast cancer patients with probable oligometastatic disease.
最近，一些特定的正电子发射断层扫描（PET）示踪配体的进展，例如基于前列腺特异性膜抗原（PSMA）的 PET 成像，极大地提高了 PET 成像的灵敏度和特异性。18F-氟雌二醇（FES）是一种新型的 PET 示踪剂，已被证明对乳腺癌中的雌激素受体（ER）具有很高的特异性。本病例描述了使用 FES-PET 进一步描述局部晚期 ER 阳性乳腺癌患者的孤立肩胛骨病变。在病变中显示 FES 摄取时，确定其代表转移性疾病，从而避免了进一步的活检及其相关的发病率。本病例证明了 FES PET-CT 在管理可能发生寡转移疾病的 ER 阳性乳腺癌患者中的潜在诊断应用。
